Related Experiment Video
Updated: Jan 16, 2026

12:19
Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
Published on: June 7, 2024
1.9K
In Vitro Model for Studying Interaction of Immune Cells and Cancer Cells.
Thanh Hoa Vo1,2, Amie Menton1, Orla O'Donovan1,2
1Department of Science, School of Science and Computing, South East Technological University, Waterford, Ireland.
Methods in Molecular Biology (Clifton, N.J.)
|September 30, 2025
Summary
This study explores indirect coculture to understand how breast cancer cells influence immune cells via secreted factors. This paracrine signaling model reveals crucial interactions within the tumor microenvironment (TME).
Area of Science:
- Oncology
- Immunology
- Cell Biology
Background:
- The tumor microenvironment (TME) comprises diverse cells crucial for tumor progression and therapy response.
- Cell-to-cell communication within the TME dictates tumor growth, metastasis, and treatment efficacy.
Purpose of the Study:
- To investigate the paracrine signaling between breast cancer cells and immune cells within the TME.
- To elucidate how soluble factors secreted by cancer cells modulate immune cell behavior in vitro.
Main Methods:
- Utilized indirect coculture systems with transwell inserts to separate cell types while allowing communication.
- Cultured breast cancer cell lines with immune cells to analyze paracrine interactions.
- Focused on the transfer of soluble factors, preventing direct cell-to-cell contact.
Main Results:
- Demonstrated that breast cancer cell lines secrete soluble factors that modulate immune cells.
- Highlighted the role of paracrine signaling in mediating cross-talk within the TME.
- Established indirect coculture as a model to study the impact of soluble factors on immune and cancer cells.
Conclusions:
- Indirect coculture effectively models paracrine communication in the TME.
- Soluble factors play a significant role in the interaction between breast cancer and immune cells.
- Understanding these interactions is key to developing novel cancer therapies.

